Opus Genetics, Inc. (IRD) Tops Q2 EPS by 7c

Opus Genetics, Inc. (NASDAQ: IRD) reported Q2 EPS of ($0.12), $0.07 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $2.88 million versus the consensus estimate of $4.04 million.

For earnings history and earnings-related data on Opus Genetics, Inc. (IRD) click here.

You May Also Be Interested In

• Antero Resources (AR) PT Raised to $47 at Benchmark on Natural Gas Bull Case
• Dyadic International, Inc. (DYAI) Misses Q2 EPS by 2c
• Avino Silver & Gold Mines (ASM) Misses Q2 EPS by 4c